emtricitabine has been researched along with Weight Gain in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 12 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Lazzarotto, T; Miani, T; Nuti, B; Viale, P | 1 |
| Brunet, L; Fusco, GP; Fusco, JS; Hsu, RK; Lamori, JC; Mounzer, K | 1 |
| Galindo, MJ; González, CS; Lillo, IS; Rodríguez, AP | 1 |
| Allavena, C; Arvieux, C; Becker, A; Cabié, A; Chéret, A; Delpierre, C; Duvivier, C; Hocqueloux, L; Joly, V; Menard, A | 1 |
| Guevara-Maldonado, MF; Kammar-García, A; Mancilla-Galindo, J; Mata-Marín, JA; Ortiz-Hernández, A; Pérez-Barragán, E; Pérez-Cavazos, S | 1 |
| Hachey, D; Shiluama, R; Singu, BS; van Woerden, I | 1 |
| Chuang, YC; Hung, CC; Kuo, PH; Liu, WC; Sun, HY; Wu, PY | 1 |
| Baker, D; Bloch, M; Carr, M; Hoy, JF; Richardson, R; Tong, W | 1 |
| Berruti, M; Briano, F; Di Biagio, A; Taramasso, L | 1 |
| Barbini, B; Campbell, L; Gilleece, Y; Hamzah, L; Ibrahim, F; Kegg, S; Post, FA; Samarawickrama, A; Vincent, R; Waters, L | 1 |
| DeMarais, P; Max, B | 1 |
| Hill, A; Hindley, L; McCann, K; Qavi, A; Serenata, C; Shah, S; Simmons, B; Sokhela, S; Venter, WDF | 1 |
2 trial(s) available for emtricitabine and Weight Gain
| Article | Year |
|---|---|
Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin Resistance; Kidney; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2021 |
Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes.
Topics: Adult; Anti-HIV Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Emtricitabine; Female; HIV Infections; Humans; Male; Retrospective Studies; South Africa; Weight Gain | 2021 |
10 other study(ies) available for emtricitabine and Weight Gain
| Article | Year |
|---|---|
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Topics: Alanine; Amides; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Weight Gain | 2022 |
Weight gain in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Pyridones; Tenofovir; Weight Gain | 2023 |
Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Propensity Score; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Weight Gain | 2023 |
Weight gain in Namibians with HIV switching from efavirenz to dolutegravir.
Topics: Anti-HIV Agents; Benzoxazines; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipidemias; Emtricitabine; Female; HIV Seropositivity; Humans; Lipids; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Weight Gain | 2020 |
Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeks.
Topics: Adult; Anti-HIV Agents; Body Mass Index; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Raltegravir Potassium; Tenofovir; Weight Gain | 2020 |
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Weight Gain | 2020 |
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Quinolones; Tenofovir; Weight Gain | 2021 |